This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends strict targets for blood glucose control to reduce the long-term risks associated with diabetes.
In November 2016, recommendations 1.2.115 and 1.3.52 were amended to add information on when eye screening should begin and referral for eye screening should happen.
Who is it for?
- Healthcare professionals that care for children and young people with diabetes
- Commissioners and providers of diabetes services
- Children and young people with type 1 or type 2 diabetes, and their families and carers.
The guideline includes recommendations on:
- management of type 1 and type 2 diabetes
- diagnosis and management of diabetic ketoacidosis in children and young people with type 1 and type 2 diabetes
- service provision.
Guideline development process
This guideline updates and replaces the sections for children and young people in NICE guideline CG15.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.